GGrantIndex
← Leaderboards

Marianne Manchester

Scripps Research Institute

$18,521,680
Attributed
$19,966,562
Total exposure
9
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.8M · FY200516
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$19,966,562 · 9

By mechanism

P01$9,227,557 · 1
R01$9,136,326 · 4
U19$958,997 · 1
R21$522,226 · 1
R29$85,677 · 1
P41$35,779 · 1

Top collaborators

Most similar at Scripps Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoResearch StudyIn VitroProteinsBaseBinding (Molecular Function)PropertyPeptidesAnthrax ToxinAntitoxinsToxinCellsVaccinesPathogenesisAnthrax Toxin ReceptorsDesignCostImageVirusBacillus AnthracisAnthrax DiseaseChimeric ProteinsInsect VirusesAntigens

Grant awards (32)

Metabolomics Core$308,324
U19 · FY2016 · AI · contact PI
Metabolomics Core$310,000
U19 · FY2015 · AI · contact PI
Metabolomics Core$340,673
U19 · FY2013 · AI · contact PI
Receptor Decoy Inhibitor of Anthrax Toxin$464,225
R01 · FY2012 · AI
Receptor Decoy Inhibitor of Anthrax Toxin$464,225
R01 · FY2011 · AI
Receptor Decoy Inhibitor of Anthrax Toxin$468,914
R01 · FY2010 · AI
Multivalent VAccines for Biodefense$261,113
R21 · FY2010 · AI
USING VIRAL NANOPARTICLES TO TARGET CANCER$747,886
R01 · FY2009 · CA · contact PI
Receptor Decoy Inhibitor of Anthrax Toxin$473,650
R01 · FY2009 · AI
Multivalent VAccines for Biodefense$261,113
R21 · FY2009 · AI
USING VIRAL NANOPARTICLES TO TARGET CANCER$20,026
R01 · FY2009 · CA · contact PI
USING VIRAL NANOPARTICLES TO TARGET CANCER$746,719
R01 · FY2008 · CA · contact PI
Receptor Decoy Inhibitor of Anthrax Toxin$496,525
R01 · FY2008 · AI
Multivalent display of anthrax toxin inhibitors$2,064,948
P01 · FY2007 · AI · contact PI
USING VIRAL NANOPARTICLES TO TARGET CANCER$726,519
R01 · FY2007 · CA · contact PI
COLUMN FRACTION SCREENING OF CPMV PARTICLES$35,779
P41 · FY2007 · RR · contact PI
Multivalent display of anthrax toxin inhibitors$2,068,666
P01 · FY2006 · AI · contact PI
USING VIRAL NANOPARTICLES TO TARGET CANCER$726,937
R01 · FY2006 · CA · contact PI
Multivalent display of anthrax toxin inhibitors$2,060,333
P01 · FY2005 · AI
USING VIRAL NANOPARTICLES TO TARGET CANCER$722,829
R01 · FY2005 · CA
Multivalent display of anthrax toxin inhibitors$2,000,047
P01 · FY2004 · AI
ROLE OF CD46 IN MEASLES ENTRY AND IMMUNOSUPPRESSION$310,625
R01 · FY2004 · AI
Multivalent display of anthrax toxin inhibitors$1,033,563
P01 · FY2003 · AI
PLANT VIRUS CHIMERAS AS VACCINES AND ANTIVIRALS$398,925
R01 · FY2003 · AI
ROLE OF CD46 IN MEASLES ENTRY AND IMMUNOSUPPRESSION$310,625
R01 · FY2003 · AI
PLANT VIRUS CHIMERAS AS VACCINES AND ANTIVIRALS$359,033
R01 · FY2002 · AI
ROLE OF CD46 IN MEASLES ENTRY AND IMMUNOSUPPRESSION$279,563
R01 · FY2002 · AI
PLANT VIRUS CHIMERAS AS VACCINES AND ANTIVIRALS$398,925
R01 · FY2001 · AI
ROLE OF CD46 IN MEASLES ENTRY AND IMMUNOSUPPRESSION$310,625
R01 · FY2001 · AI
PLANT VIRUS CHIMERAS AS VACCINES AND ANTIVIRALS$398,925
R01 · FY2000 · AI
ROLE OF CD46 IN MEASLES ENTRY AND IMMUNOSUPPRESSION$310,625
R01 · FY2000 · AI
VIRUS-RECEPTOR INTERACTIONS IN MEASLES PATHOGENESIS$85,677
R29 · FY2000 · AI